You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ICIs

Showing 1 - 25 of 178
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Immunonutrition Trial in Hefei (Whole-course Immunonutrition Combined

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • +3 more
  • Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs
  • Hefei, China
    Anhui provincial hospital
Apr 16, 2023

Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular

Completed
  • AKI Incidence of Cancer Patients Receiving AntiVEGF or ICIs
  • Wenzhou, Zhejiang, China
    The First Affiliated Hospital of Wenzhou Medical University
Nov 6, 2023

NSCLC Stage III Trial (radiotherapy, Platinum-Based Drug, Immunotherapy)

Not yet recruiting
  • Non-small Cell Lung Cancer Stage III
  • radiotherapy
  • +3 more
  • (no location specified)
Sep 10, 2023

Sequential Regorafenib Plus ICIs After HAIC for Advanced

Recruiting
  • Hepatocellular Carcinoma
  • Regorafenib combine with ICIs
  • Guangzhou, Guangdong, China
  • +1 more
Oct 15, 2022

ICIs Combined With Chemotherapy in Advanced NSCLC

Recruiting
  • Lung Cancer, Nonsmall Cell
    • Nanjing, Jiangsu, China
      Shuhua Han
    Feb 10, 2023

    Lung Cancer Trial in Shanghai (chemo plus TCM 1&ICIs plusTCM2 , chemo plus TCM 1 &ICIs plus TCM2 )

    Not yet recruiting
    • Lung Cancer
    • chemotherapy plus TCM 1&ICIs plusTCM2 placebo
    • chemotherapy plus TCM 1placebo &ICIs plus TCM2 placebo
    • Shanghai, Shanghai, China
      YueYang Hosptial of Intergrated Traditional Chinese and Western
    Apr 17, 2023

    Safety of ICIs and TKIs Therapy for HCC

    Recruiting
    • Hepatocellular Carcinoma
    • +2 more
    • Lenvatinib Oral Product
    • +2 more
    • Wuhan, Hubei, China
      Tongji Hospital, Tongji Medical College, Huazhong University of
    Jun 11, 2022

    Efficacy and Safety of ICIs as First-line Therapy for Advanced

    Not yet recruiting
    • Malignant Tumor
    • +2 more
      • Chongqing, Chongqing, China
        the second affiliated hospital of Army medical university
      May 16, 2023

      Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients

      Recruiting
      • Lung Neoplasms
      • +3 more
      • Observation
      • Shanghai, China
        Shanghai Chest Hospital
      Mar 14, 2022

      ICIs Plus Angiogenesis Inhibitors for Treatment of Advanced

      Completed
      • NSCLC
      • Immune checkpoint inhibitors plus angiogenesis inhibitors
      • Immune checkpoint inhibitors without angiogenesis inhibitors
      • Suzhou, Jiangsu, China
        The Affiliated Suzhou Hospital of Nanjing Medical University
      Jan 17, 2023

      Lung Cancer, Immune Checkpoint Inhibitor, Radiotherapy Trial in Chongqing (Super-hyperfractionation Pulse Radiotherapy)

      Recruiting
      • Lung Cancer
      • +2 more
      • Super-hyperfractionation Pulse Radiotherapy
      • Chongqing, Chongqing, China
      • +1 more
      Feb 22, 2023

      Small Cell Lung Cancer, Immunotherapy Trial in Changsha (chronic psychological stress)

      Recruiting
      • Small Cell Lung Cancer
      • Immunotherapy
      • chronic psychological stress
      • Changsha, Hunan, China
        Department of Oncology, The Second Xiangya Hospital, Central Sou
      Jul 22, 2023

      Primary Liver Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma Trial in China (Observation)

      Recruiting
      • Primary Liver Cancer
      • +3 more
      • Observation
      • Beijing, Beijing, China
      • +4 more
      Jun 14, 2022

      Hepatocellular Carcinoma Trial in Guangzhou (digital subtraction angiography., FOLFOX (oxaliplatin , leucovorin , fluorouracil ,

      Recruiting
      • Hepatocellular Carcinoma
      • digital subtraction angiography.
      • FOLFOX (oxaliplatin , leucovorin , fluorouracil , and fluorouracil )
      • Guangzhou, Guangdong, China
        Department of Minimally Invasive and Interventional Radiology, L
      Feb 7, 2023

      Head and Neck Squamous Cell Carcinoma Trial in Candiolo (inulin, Pembrolizumab, Nivolumab)

      Recruiting
      • Head and Neck Squamous Cell Carcinoma
      • inulin
      • +2 more
      • Candiolo, Turin, Italy
        Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo
      Apr 7, 2023

      Lung Cancer, Chronic Stress Disorder, Immune Checkpoint Inhibitors Trial in Changsha (Gut microbiota detection, Peripheral

      Recruiting
      • Lung Cancer
      • +2 more
      • Gut microbiota detection
      • Peripheral immune cells signature detaction
      • Changsha, Hunan, China
        Department of Oncology, The Second Xiangya Hospital, Central Sou
      Jul 26, 2022

      Immune-Mediated Hepatitis, Liver Failure, Hepatocellular Carcinoma Trial in Guangzhou (DPMAS+LPE, PE, Comprehensive internal

      Not yet recruiting
      • Immune-Mediated Hepatitis
      • +2 more
      • DPMAS+LPE
      • +2 more
      • Guangzhou, Guangdong, China
        Third Affiliated Hospital of Sun Yat-sen University
      Jul 30, 2022

      Non Small Cell Lung Cancer Metastatic Trial (Pembrolizumab in Combination with Plinabulin and Docetaxel)

      Not yet recruiting
      • Non Small Cell Lung Cancer Metastatic
      • Pembrolizumab in Combination with Plinabulin and Docetaxel
      • (no location specified)
      Oct 28, 2022

      TACE in Combination With ICIs for HCC: a Real-world Study

      Recruiting
      • Hepatocellular Carcinoma
      • TACE+ICIs
      • TACE
      • Nanjing, China
        Gao-Jun Teng
      Jul 22, 2021

      NSCLC Trial in Guangzhou (ICI, Chemotherapy, Placebo)

      Recruiting
      • Non-small Cell Lung Cancer
      • Guangzhou, Guangdong, China
        Guangdong Provincial Hospital of Traditional Chinese Medicine
      Aug 11, 2022

      Efficiency and Safety of ICIs in Different Malignancies

      Recruiting
      • Melanoma
      • +3 more
      • Genetic tests of the available tumor and plasma samples
      • Moscow', Москва, Russian Federation
        N.N. Blokhin Russian Cancer Research Center
      Dec 26, 2021

      Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for

      Recruiting
      • Hepatocellular Carcinoma Non-resectable
      • HAIC
      • +8 more
      • Quanzhou, Fujian, China
      • +1 more
      Jan 26, 2023

      Tumor, Solid Trial in United States (agenT-797, Approved ICIs)

      Recruiting
      • Tumor, Solid
      • Los Angeles, California
      • +8 more
      Oct 21, 2022

      Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for

      Recruiting
      • Hepatocellular Carcinoma Non-resectable
      • TACE
      • +8 more
      • Quanzhou, Fujian, China
      • +3 more
      Jan 29, 2023

      ICIS in Burn Patients Compared to Other Inflammatory Markers

      Recruiting
      • Infection, Bacterial
      • +2 more
      • Flow fluorescence cytometry
      • Prague, Czechia
        University Hospital Kralovske Vinohrady
      May 27, 2021